news
T-cell engagers set to drive immuno-oncology market
Amid intensifying market competition, the next-generation therapies could shape the future of oncology.
List view / Grid view
Oncology
news
Bristol Myers Squibb names new Head of Development
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
news
ADC oncology therapy market to value over $36b by 2029
With antibody-drug conjugates (ADCs) gaining favour as oncology treatments, research shows Daiichi Sankyo, Seagen and Roche are currently three of the market's most important players.
news
Astellas to advance oncology CAR-T therapy
An investment of $50 million by Astellas Pharma in Poseida Therapeutics’ Phase I allogeneic CAR-T product candidate for solid tumour indications is set to advance the cancer immunotherapy field.
news
Will ESR1-mutated breast cancer treatment gain approval?
If approved by the European Commission (EC), ORSERDU® (elacestrant) would be the first treatment for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations.
news
UK ATMP clinical trials report 2022 published
T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
news
Oligonucleotide synthesis market to reach $16.7 billion by 2027
Ongoing clinical trials for oligonucleotide-based therapies will propel the oligonucleotide synthesis market to reach $16.7 billion by 2027, states a new report.
news
Sanofi to sell Japanese manufacturing plant
Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
article
Issue #6 2016 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
news
ESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
news
Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
news
Initiation of HTL1071 trial triggers $10m payment to Heptares
6 July 2016 | By Victoria White, Digital Content Producer
The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
news
Positive results for Yeliva in Phase I advanced solid tumour study
4 July 2016 | By Victoria White, Digital Content Producer
Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities...
news
Xilonix demonstrates significant clinical response in colorectal cancer study
4 July 2016 | By Victoria White, Digital Content Producer
XBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)...
news
BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 | By Victoria White, Digital Content Producer
The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...
